Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.33 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.32 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.32 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.32 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19754398 | 0.84 | LMNA (0.51) | LMNACYP2C9CA1CA2CA9 | |
| SCHEMBL2597036 | 0.78 | CA2 (0.44) | LMNACYP2C9CA1CA2CA9 | |
| SCHEMBL31465290 | 0.78 | CA2 (0.44) | LMNACYP2C9CA1CA2CA9 | |
| SCHEMBL15044966 | 0.77 | CA1 (0.37) | LMNACYP2C9CA1CA2CA9 | |
| SCHEMBL8024678 | 0.73 | CYP2C9 (0.83) | LMNACYP2C9CA1CA2CA9 | |
| SCHEMBL4011978 | 0.69 | CA1 (0.54) | LMNACA1CA2CA9PTGDR2 | |
| SCHEMBL14606392 | 0.69 | PTGDR2 (0.46) | LMNACYP2C9CA1CA2CA9 | |
| SCHEMBL13547786 | 0.69 | CA1 (0.54) | LMNACYP2C9CA1CA2CA9 | |
| SCHEMBL25827150 | 0.68 | GPR3 (0.32) | — | |
| SCHEMBL7603160 | 0.66 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | LMNA 2220/4885CYP2C9 340/4885CA1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.